Cargando…
Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A
BACKGROUND: Nucleophosmin gene (NPM1) mutation may be a good molecular marker for assessing the clinical status and predicting the outcomes in AML patients. We evaluated the applicability of NPM1 type A mutation (NPM1-mutA) quantitation for this purpose. METHODS: Twenty-seven AML patients with norma...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Laboratory Medicine
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940481/ https://www.ncbi.nlm.nih.gov/pubmed/27374703 http://dx.doi.org/10.3343/alm.2016.36.5.399 |
_version_ | 1782442149254529024 |
---|---|
author | Jo, Su Yeon Park, Sang Hyuk Kim, In-Suk Yi, Jongyoun Kim, Hyung-Hoi Chang, Chulhun L. Lee, Eun Yup Cho, Young-Uk Jang, Seongsoo Park, Chan-Jeoung Chi, Hyun-Sook |
author_facet | Jo, Su Yeon Park, Sang Hyuk Kim, In-Suk Yi, Jongyoun Kim, Hyung-Hoi Chang, Chulhun L. Lee, Eun Yup Cho, Young-Uk Jang, Seongsoo Park, Chan-Jeoung Chi, Hyun-Sook |
author_sort | Jo, Su Yeon |
collection | PubMed |
description | BACKGROUND: Nucleophosmin gene (NPM1) mutation may be a good molecular marker for assessing the clinical status and predicting the outcomes in AML patients. We evaluated the applicability of NPM1 type A mutation (NPM1-mutA) quantitation for this purpose. METHODS: Twenty-seven AML patients with normal karyotype but bearing the mutated NPM1 were enrolled in the study, and real-time quantitative PCR of NPM1-mutA was performed on 93 bone marrow (BM) samples (27 samples at diagnosis and 56 at follow-up). The NPM1-mutA allele burdens (represented as the NPM1-mutA/Abelson gene (ABL) ratio) at diagnosis and at follow-up were compared. RESULTS: The median NPM1-mutA/ABL ratio was 1.3287 at diagnosis and 0.092 at 28 days after chemotherapy, corresponding to a median log(10) reduction of 1.7061. Significant correlations were observed between BM blast counts and NPM1-mutA quantitation results measured at diagnosis (γ=0.5885, P=0.0012) and after chemotherapy (γ=0.5106, P=0.0065). Total 16 patients achieved morphologic complete remission at 28 days after chemotherapy, and 14 (87.5%) patients showed a >3 log(10) reduction of the NPM1-mutA/ABL ratio. The NPM1-mutA allele was detected in each of five patients who had relapsed, giving a median increase of 0.91-fold of the NPM1-mutA/ABL ratio at relapse over that at diagnosis. CONCLUSIONS: The NPM1-mutA quantitation results corresponded to BM assessment results with high stability at relapse, and could predict patient outcomes. Quantitation of the NPM1-mutA burden at follow-up would be useful in the management of AML patients harboring this gene mutation. |
format | Online Article Text |
id | pubmed-4940481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | The Korean Society for Laboratory Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-49404812016-09-01 Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A Jo, Su Yeon Park, Sang Hyuk Kim, In-Suk Yi, Jongyoun Kim, Hyung-Hoi Chang, Chulhun L. Lee, Eun Yup Cho, Young-Uk Jang, Seongsoo Park, Chan-Jeoung Chi, Hyun-Sook Ann Lab Med Original Article BACKGROUND: Nucleophosmin gene (NPM1) mutation may be a good molecular marker for assessing the clinical status and predicting the outcomes in AML patients. We evaluated the applicability of NPM1 type A mutation (NPM1-mutA) quantitation for this purpose. METHODS: Twenty-seven AML patients with normal karyotype but bearing the mutated NPM1 were enrolled in the study, and real-time quantitative PCR of NPM1-mutA was performed on 93 bone marrow (BM) samples (27 samples at diagnosis and 56 at follow-up). The NPM1-mutA allele burdens (represented as the NPM1-mutA/Abelson gene (ABL) ratio) at diagnosis and at follow-up were compared. RESULTS: The median NPM1-mutA/ABL ratio was 1.3287 at diagnosis and 0.092 at 28 days after chemotherapy, corresponding to a median log(10) reduction of 1.7061. Significant correlations were observed between BM blast counts and NPM1-mutA quantitation results measured at diagnosis (γ=0.5885, P=0.0012) and after chemotherapy (γ=0.5106, P=0.0065). Total 16 patients achieved morphologic complete remission at 28 days after chemotherapy, and 14 (87.5%) patients showed a >3 log(10) reduction of the NPM1-mutA/ABL ratio. The NPM1-mutA allele was detected in each of five patients who had relapsed, giving a median increase of 0.91-fold of the NPM1-mutA/ABL ratio at relapse over that at diagnosis. CONCLUSIONS: The NPM1-mutA quantitation results corresponded to BM assessment results with high stability at relapse, and could predict patient outcomes. Quantitation of the NPM1-mutA burden at follow-up would be useful in the management of AML patients harboring this gene mutation. The Korean Society for Laboratory Medicine 2016-09 2016-06-24 /pmc/articles/PMC4940481/ /pubmed/27374703 http://dx.doi.org/10.3343/alm.2016.36.5.399 Text en © The Korean Society for Laboratory Medicine. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Jo, Su Yeon Park, Sang Hyuk Kim, In-Suk Yi, Jongyoun Kim, Hyung-Hoi Chang, Chulhun L. Lee, Eun Yup Cho, Young-Uk Jang, Seongsoo Park, Chan-Jeoung Chi, Hyun-Sook Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A |
title | Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A |
title_full | Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A |
title_fullStr | Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A |
title_full_unstemmed | Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A |
title_short | Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A |
title_sort | correlation of npm1 type a mutation burden with clinical status and outcomes in acute myeloid leukemia patients with mutated npm1 type a |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940481/ https://www.ncbi.nlm.nih.gov/pubmed/27374703 http://dx.doi.org/10.3343/alm.2016.36.5.399 |
work_keys_str_mv | AT josuyeon correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT parksanghyuk correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT kiminsuk correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT yijongyoun correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT kimhyunghoi correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT changchulhunl correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT leeeunyup correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT choyounguk correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT jangseongsoo correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT parkchanjeoung correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea AT chihyunsook correlationofnpm1typeamutationburdenwithclinicalstatusandoutcomesinacutemyeloidleukemiapatientswithmutatednpm1typea |